{"ctNumber":"2024-516022-63-00","ctStatus":"Authorised","startDateEU":"2024-03-21","decisionDate":"2024-11-06T17:16:25.757","publishDate":"2026-08-14T03:35:22.228855901","ctPublicStatusCode":4,"authorizedApplication":{"authorizedPartI":{"id":140223,"rowSubjectCount":0,"products":[{"id":584279,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11633493","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11633493","prodAuthStatus":1,"prodName":"[18F]MNI-659","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE","euSubstNumber":"SUB406038","nameOrg":"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS","productSubstances":[{"productPk":"11633493","substancePk":"406043","nameOrg":"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE","substanceEvCode":"SUB406038"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"µg microgram(s)","maxDailyDoseAmount":"5","doseUomTotal":"µg microgram(s)","maxTotalDoseAmount":"10","maxTreatmentPeriod":2,"timeUnitCode":"1","evCode":"PRD11633493","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":true,"productName":"[18F]MNI-659","jsonActiveSubstanceNames":"2-[2-[3-[4-(2-(18f)fluoranylethoxy)phenyl]-7-methyl-4-oxoquinazolin-2-yl]ethyl]-4-propan-2-yloxyisoindole-1,3-dione","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"I2BIO-HD. Innovative Imaging and cognitive BIOmarkers to predict Huntington’s Disease progression","fullTitleTranslations":[{"id":11842088,"uuid":"a3f91b77-16e0-4663-b47e-a3de207ab961","attributeTranslation":"Imagerie Innovante et BIOmarqueurs cognitifs pour prédire la progression de la maladie de Huntington","language":10,"languageDescription":"French"}],"publicTitle":"Innovative Imaging and Cognitive BIOmarkers to Predict Huntington's Disease Progression","publicTitleTranslations":[],"shortTitle":"APHP210360","secondaryIdentifyingNumbers":{"nctNumber":{"id":571186,"number":"NCT05808153"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"5","trialCategory":"2","justificationForTrialCategory":"Phase III","trialCategoryId":129602},"medicalCondition":{"partIMedicalConditions":[{"id":146866,"medicalCondition":"Patients with symptomatic and pre-symptomatic Huntington's disease","medicalConditionTranslations":[{"id":11842070,"uuid":"a63f1b8e-194a-4136-a265-638a4d07abd1","attributeTranslation":"Patients atteints de la maladie de de Huntington symptomatique et présymptomatiques","language":10,"languageDescription":"French"}],"isConditionRareDisease":true}],"meddraConditionTerms":[{"termId":100000113334,"version":"20.0","level":"PT","termName":"Huntington's disease","classificationCode":"10070668","organClass":100000004850,"active":false}]},"trialObjective":{"trialScopes":[{"code":"13","otherDescription":"Definition of a composite score as a tool for predicting disease progression","trialScopeId":426276}],"mainObjective":"Identify biomarkers, used singly or in combination, that enable sensitive measurement of the progression of Huntington's disease from the presymptomatic stages onwards, within the framework of clinical trials.","mainObjectiveTranslations":[{"id":11842093,"uuid":"af6d13b6-f2f2-4130-af08-395074e3ce00","attributeTranslation":"Identifier les biomarqueurs utilisés isolément ou combinés permettant une mesure sensible de l'évolution de la maladie de Huntington dès les stades présymptomatiques, dans le cadre d’essais cliniques.","language":10,"languageDescription":"French"}],"secondaryObjectives":[{"id":501237,"number":1,"secondaryObjective":"Identify patient profiles and HD progression trajectories (unsupervised analyses)","secondaryObjectiveTranslations":[{"id":11842094,"uuid":"65b6a897-5a40-4577-b663-bf12062a35fc","attributeTranslation":"Identifier des profils de patients et des trajectoires de progression de la MH (analyses non supervisées)","language":10,"languageDescription":"French"}]},{"id":501238,"number":2,"secondaryObjective":"Identify the best predictive biomarkers, individually or in combination, and establish their prognostic value on disease progression (supervised analyses)","secondaryObjectiveTranslations":[{"id":11842095,"uuid":"e884e1d5-917a-45d6-bb25-b547af32ea4e","attributeTranslation":"Identifier les meilleurs biomarqueurs prédicteurs, isolément ou combinés, et établir leur valeur pronostique sur l'évolution de la maladie (analyses supervisées)","language":10,"languageDescription":"French"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":954356,"number":1,"principalInclusionCriteria":"For all participants: - Age ≥18 years and ≤65 years; - Information and collection of written consent; - Affiliation with a social security plan, beneficiary or beneficiary's right","principalInclusionCriteriaTranslations":[{"id":11842089,"uuid":"8463d18b-71cd-4242-a552-e857e0ca4833","attributeTranslation":"Pour tous les participants : \n- Age ≥18ans et ≤65 ans\n- Information et recueil du consentement écrit\n- Affiliation à un régime de sécurité sociale, bénéficiaire ou ayant droit","language":10,"languageDescription":"French"}]},{"id":954357,"number":2,"principalInclusionCriteria":"For Healthy volunteers (control): - UHDRS functional score TFC = 13; - Motor UHDRS score TMS < 6; - With no known genetic disease and no direct relationship to an HD patient or family ancestors carrying the HD mutation (or knowing their genetic status with CAG < 36)","principalInclusionCriteriaTranslations":[{"id":11842090,"uuid":"5fc6c998-64af-40a2-b690-3bb0b7b0c601","attributeTranslation":"Pour les contrôles (volontaires sains):\n- score UHDRS fonctionnel TFC = 13\n- score UHDRS moteur TMS < 6\n- Sans maladie génétique connue et sans relation directe avec un patient MH ni ascendant familiaux porteurs de la mutation MH (ou connaissant son statut génétique avec CAG < 36).","language":10,"languageDescription":"French"}]},{"id":954358,"number":3,"principalInclusionCriteria":"For Symptomatic huntington's disease patients: - Number of GACs ≥ 40;  - CAP score ≥ 250; - 10 ≤ TFC ≤ 13; - TMS >5 if TFC=13; - Diagnostic confidence level =4; - Age of onset of disease > 20 years ; - Patient physically able to sign consent","principalInclusionCriteriaTranslations":[{"id":11842091,"uuid":"3d4e9afb-a130-4297-91c3-b5ed577811f1","attributeTranslation":"Pour les patients symptomatiques MH :\n- Nombre de CAG ≥ 40\n- CAP score ≥ 250\n- 10 ≤ TFC ≤ 13\n- TMS >5 si TFC=13\n- Niveau de confiance du diagnostic =4\n- Age début de la maladie > 20 ans\n- Patient en capacité physique de signer le consentement","language":34,"languageDescription":"French (France)"}]},{"id":954359,"number":4,"principalInclusionCriteria":"For Pre-symptomatic Huntington's disease patients: - Number of GACs ≥ 40; - CAP score ≥250; - TFC = 13; - TMS < 6; - Patient physically able to sign consent","principalInclusionCriteriaTranslations":[{"id":11842092,"uuid":"14471a06-128e-4b96-8f6b-4ace3782e527","attributeTranslation":"Pour les patients présymptomatiques (preMH) :\n- Nombre de CAG ≥ 40\n- CAP score ≥250\n- TFC = 13\n- TMS < 6\n- Patient en capacité physique de signer le consentement","language":10,"languageDescription":"French"}]}],"principalExclusionCriteria":[{"id":1630009,"number":1,"principalExclusionCriteria":"Participant under guardianship or curatorship","principalExclusionCriteriaTranslations":[{"id":11842074,"uuid":"255e779f-9c3b-460e-b77a-ad6c6411c0bb","attributeTranslation":"Participant sous tutelle ou curatelle","language":10,"languageDescription":"French"}]},{"id":1630010,"number":10,"principalExclusionCriteria":"Pregnant or breastfeeding woman","principalExclusionCriteriaTranslations":[{"id":11842075,"uuid":"35faaf80-129f-4fa1-b82e-0b47bee72692","attributeTranslation":"Femme enceinte, allaitante","language":10,"languageDescription":"French"}]},{"id":1630011,"number":11,"principalExclusionCriteria":"Person under state medical aid","principalExclusionCriteriaTranslations":[{"id":11842076,"uuid":"3b10d50d-ddd7-41e5-9e0a-de8b5fb88438","attributeTranslation":"Personne sous AME","language":10,"languageDescription":"French"}]},{"id":1630012,"number":12,"principalExclusionCriteria":"Person deprived of liberty","principalExclusionCriteriaTranslations":[{"id":11842077,"uuid":"6de25c24-e9f7-4718-bcb5-bab65b524051","attributeTranslation":"Personne privée de liberté","language":10,"languageDescription":"French"}]},{"id":1630013,"number":13,"principalExclusionCriteria":"Person participating or having participated in an interventional study for less than 3 months or without time limit in a trial of neural transplants or gene therapy.","principalExclusionCriteriaTranslations":[{"id":11842078,"uuid":"69e7382e-a13d-4577-a8fa-b9ec3b3f9647","attributeTranslation":"Personne participant ou ayant participé à une étude interventionnelle depuis moins de 3 mois ou sans limite de délai à un essai de greffes neuronales ou de thérapie génique","language":10,"languageDescription":"French"}]},{"id":1630014,"number":14,"principalExclusionCriteria":"Person participating or having participated in a research protocol with a radiopharmaceutical injection for less than 12 months.","principalExclusionCriteriaTranslations":[{"id":11842079,"uuid":"063c0455-5283-4bfa-a217-dd5bf8375e94","attributeTranslation":"Personne participant ou ayant participé à un protocole de recherche avec injection d’un radiopharmaceutique depuis moins de 12 mois","language":10,"languageDescription":"French"}]},{"id":1630015,"number":2,"principalExclusionCriteria":"Neurological or psychiatric disorder unrelated to HD","principalExclusionCriteriaTranslations":[{"id":11842080,"uuid":"68beb20d-e8cd-4f1a-a366-03c11001ce43","attributeTranslation":"Trouble neurologique ou psychiatrique non relié à la MH","language":10,"languageDescription":"French"}]},{"id":1630016,"number":3,"principalExclusionCriteria":"Intercurrent illness that may impact participant's performance","principalExclusionCriteriaTranslations":[{"id":11842081,"uuid":"9fb4524e-4116-45e2-bdc6-05bb63122648","attributeTranslation":"Maladie intercurrente pouvant impacter les performances des participants","language":10,"languageDescription":"French"}]},{"id":1630017,"number":4,"principalExclusionCriteria":"Chronic progressive neurological disease","principalExclusionCriteriaTranslations":[{"id":11842082,"uuid":"f9a13ced-514f-4431-8de5-b3375bf7be1c","attributeTranslation":"Maladie neurologique chronique évolutive","language":10,"languageDescription":"French"}]},{"id":1630018,"number":5,"principalExclusionCriteria":"Claustrophobia","principalExclusionCriteriaTranslations":[{"id":11842083,"uuid":"955230cd-c490-4614-b729-3dede6b6688c","attributeTranslation":"Claustrophobie","language":10,"languageDescription":"French"}]},{"id":1630019,"number":6,"principalExclusionCriteria":"Brain injury unrelated to HD","principalExclusionCriteriaTranslations":[{"id":11842084,"uuid":"a3ef3aa1-2ae2-43d0-a551-e22ded45ae97","attributeTranslation":"Lésion cérébrale non reliée à la MH","language":10,"languageDescription":"French"}]},{"id":1630020,"number":7,"principalExclusionCriteria":"Pacemaker, intracorporeal metal, intracerebral clip, any metallic foreign body: implantable cardiac electronic device such as pacemakers, implantable cardioverter defibrillators etc., metallic intraocular foreign bodies, implantable neurostimulation systems, cochlear implants/ear implants, drug infusion pumps (insulin administration, analgesic drugs), or chemotherapy pumps): if possible, the patient should remove the device.","principalExclusionCriteriaTranslations":[{"id":11842085,"uuid":"1e944103-3d30-47b3-a6c6-1c24e50529b7","attributeTranslation":"Pacemaker, métal intracorporel, clip intracérébral, tout corps étranger métallique : dispositif électronique cardiaque implantable (CIED) tel que stimulateurs cardiaques, défibrillateurs automatiques implantables (DCI) etc., corps étrangers intraoculaires métalliques, systèmes de neurostimulation implantables, implants cochléaires/implants auriculaires, pompes à perfusion de médicaments (administration d'insuline, médicaments analgésiques) , ou pompes de chimiothérapie) : si possible, le patient doit retirer le dispositif.","language":10,"languageDescription":"French"}]},{"id":1630021,"number":8,"principalExclusionCriteria":"Catheters with metal components (Swan-Ganz catheter), metal fragments such as bullets, shotgun pellets and metal shrapnel, cerebral artery aneurysm clips, magnetic dental implants, tissue expander, artificial limb, hearing aid, piercing such as pacemaker","principalExclusionCriteriaTranslations":[{"id":11842086,"uuid":"3602b8d7-adfe-4576-ad07-bdb5bbc61cf6","attributeTranslation":"Cathéters avec des composants métalliques (cathéter de Swan-Ganz), fragments métalliques tels que balles, plombs de fusil de chasse et éclats d'obus métalliques, clips d'anévrisme de l'artère cérébrale, implants dentaires magnétiques, expanseur tissulaire, membre artificiel, prothèse auditive, piercing tel que stimulateur cardiaque","language":10,"languageDescription":"French"}]},{"id":1630022,"number":9,"principalExclusionCriteria":"Known hypersensitivity to the radiopharmaceutical preparation (excipients in the radiopharmaceutical preparation)","principalExclusionCriteriaTranslations":[{"id":11842087,"uuid":"786b2492-175c-4d43-b53f-83e058f3d3ef","attributeTranslation":"Hypersensibilité connue à la préparation radiopharmaceutique (excipients de la préparation radiopharmaceutique)","language":10,"languageDescription":"French"}]}]},"endPoint":{"primaryEndPoints":[{"id":1115881,"number":1,"endPoint":"The primary endpoint will be effect size, assessed by the standardized mean difference (Cohen's d) for each biomarker between the values measured initially and their assessment at 2-year follow-up.","isPrimary":true,"endPointTranslations":[{"id":11842071,"uuid":"bf9e79b9-878b-4438-bbc8-7ccb70163ca5","attributeTranslation":"Le critère de jugement principal sera la taille d’effet évaluée par la différence moyenne standardisée (Cohen’s d) pour chacun des biomarqueurs entre les valeurs mesurées initialement et leur évaluation à 2 ans de suivi.","language":10,"languageDescription":"French"}]}],"secondaryEndPoints":[{"id":1115882,"number":1,"endPoint":"Analysis of patient profiles and progression trajectories, taking into account all available data at D0, M1, M1 bis, M12, M24 and M24 bis, will be based on socio-demographic characteristics, as well as initial clinical and paraclinical scores and their evolution over time. Clustering analyses will use statistical validation indices to determine the optimal number of clusters and provide information on cluster quality.","isPrimary":false,"endPointTranslations":[{"id":11842072,"uuid":"15b21895-bb5b-44b3-be7e-35fbed729191","attributeTranslation":"L’analyse des profils et trajectoires de progression des patients tenant compte de l’ensemble des données disponibles à J0, M1, M1 bis, M12, M24 et M24 bis s’appuiera sur les caractéristiques sociodémographiques, ainsi que sur les scores cliniques et paracliniques initiaux et leur évolution au cours du temps. Les analyses de clustering s’appuieront sur des indices statistiques de validation afin de déterminer le nombre optimal de clusters et informer sur la qualité des regroupements.","language":10,"languageDescription":"French"}]},{"id":1115883,"number":2,"endPoint":"Identification of the best biomarkers predicting an unfavorable disease course will be carried out using conventional regression and machine learning methods. Discrimination and calibration performances will be systematically evaluated and compared for each of the models constructed.","isPrimary":false,"endPointTranslations":[{"id":11842073,"uuid":"5825fe8a-b396-4b5e-a331-74e290d3799a","attributeTranslation":"L’identification des meilleurs biomarqueurs prédicteurs d’une évolution défavorable de la maladie sera réalisée en s’appuyant sur des méthodes de régression conventionnelle et d’apprentissage automatique. Les performances de discrimination et de calibration seront systématiquement évaluées et comparées pour chacun des modèles construits.","language":10,"languageDescription":"French"}]}]},"trialDuration":{"estimatedEndDate":"2029-09-21","estimatedRecruitmentStartDate":"2024-03-21"},"sourceOfMonetarySupport":[{"id":103163,"organisationName":"French Health Ministry (DGOS)"}],"populationOfTrialSubjects":{"ageRanges":[{"id":385368,"ageRangeCategoryCode":"3","ageRangeCategory":"3"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"},{"code":"1","name":"Healthy volunteers"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"1","planDescription":"All of the individual participant data collected during the trial, subject to compliance to regulations, will be available.\nDocument (Study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code) will be also available.\nData will be available immediately following publication ending 2 years after publication, with investigators whose proposed use of the data has been approved by the PI and / or the review commitee if relevant.\nProposals should be directed to drc-secretariat-promotion@aphp.fr. To gain access, data requestors will need to sign a data access agreement."}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-11","conclusionDate":"2026-08-11","therapeuticAreas":[{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}],"medicalConditions":[{"id":146866,"medicalCondition":"Patients with symptomatic and pre-symptomatic Huntington's disease","isConditionRareDisease":true}],"sponsors":[{"id":159722,"primary":true,"publicContacts":[{"id":471512,"type":"Public","functionalName":"Katia YOUSSOV - Coordinator","functionalEmailAddress":"katia.youssov@aphp.fr","telephone":"+33149812310","organisation":{"id":541199,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":471513,"type":"Scientific","functionalName":"Katia YOUSSOV - Coordinator","functionalEmailAddress":"katia.youssov@aphp.fr","telephone":"+33149812310","organisation":{"id":541199,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":541199,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"addresses":[{"id":508704,"organisation":{"id":541199,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":546346,"oneLine":"Porte 23, 1 Avenue Claude Vellefaux","addressLine1":"Porte 23","addressLine2":"1 Avenue Claude Vellefaux","addressLine3":"","addressLine4":"","city":"Paris Cedex 10","postcode":"75475","country":2012,"countryName":"France"},"isBusinessKeyValidated":true,"businessKey":"ORG-100004082"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Phase III","partOneTherapeuticAreas":[{"id":1223633,"therapeuticArea":{"code":"16","name":"Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]"}}],"productRoleGroupInfos":[{"id":434107,"comments":"[18F]MNI-659","productRoleCode":"1","productRoleName":"Test","products":[{"id":584279,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11633493","productPharmForm":"SOLUTION FOR INJECTION","euMpNumber":"PRD11633493","prodAuthStatus":1,"prodName":"[18F]MNI-659","pharmForm":"SOLUTION FOR INJECTION","activeSubstanceName":"2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE","euSubstNumber":"SUB406038","nameOrg":"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS","productSubstances":[{"productPk":"11633493","substancePk":"406043","nameOrg":"ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"2-[2-[3-[4-(2-(18F)FLUORANYLETHOXY)PHENYL]-7-METHYL-4-OXOQUINAZOLIN-2-YL]ETHYL]-4-PROPAN-2-YLOXYISOINDOLE-1,3-DIONE","substanceEvCode":"SUB406038"}],"activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"µg microgram(s)","maxDailyDoseAmount":"5","doseUomTotal":"µg microgram(s)","maxTotalDoseAmount":"10","maxTreatmentPeriod":2,"timeUnitCode":"1","evCode":"PRD11633493","devices":[],"characteristics":["3"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":true,"productName":"[18F]MNI-659","jsonActiveSubstanceNames":"2-[2-[3-[4-(2-(18f)fluoranylethoxy)phenyl]-7-methyl-4-oxoquinazolin-2-yl]ethyl]-4-propan-2-yloxyisoindole-1,3-dione","pharmaceuticalFormDisplay":"SOLUTION FOR INJECTION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":330244,"mscId":40822,"mscInfo":{"id":40822,"clinicalTrialId":16987,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-10-07","toDate":"2024-10-07","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-11-06","trialStatus":"Authorised","trialPeriod":[{"id":45711,"trialStartDate":"2024-03-21","fromDate":"2024-12-12"},{"id":45712,"trialStartDate":"2024-03-21","fromDate":"2024-12-12"}],"trialRecruitmentPeriod":[{"id":60585,"recruitmentStartDate":"2024-03-21","fromDate":"2024-12-12"},{"id":60586,"recruitmentStartDate":"2024-03-21","fromDate":"2024-12-12"}],"hasRecruitmentStarted":true,"activeTrialPeriod":{"id":62662,"trialStartDate":"2024-03-21","fromDate":"2024-12-12"},"activeTrialRecruitmentPeriod":{"recruitmentStartDate":"2024-03-21"},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":56677,"mscId":40822,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-14T09:17:03.849"},{"id":60039,"mscId":40822,"trialStatus":"Authorised","trialStatusDate":"2024-11-06T17:16:25.545"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-12","decision":"authorized","decisionDate":"2024-11-06"},"decisionDate":"2024-11-06","recruitmentSubjectCount":100,"trialSites":[{"id":2319941,"organisationAddressInfo":{"id":618561,"organisation":{"id":656431,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":668658,"oneLine":"51 Av Du Mal De Lattre De Tassigny","addressLine1":"51 Av Du Mal De Lattre De Tassigny","addressLine2":"","addressLine3":"","addressLine4":"","city":"Creteil","postcode":"94000","country":2012,"countryName":"France"},"phone":"+33149814301","email":"katia.youssov@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":2571642,"firstName":"Katia","lastName":"YOUSSOV","telephone":"+33149814301","email":"katia.youssov@aphp.fr","title":"1"},"departmentName":"Service de Neurologie"},{"id":2319942,"organisationAddressInfo":{"id":618565,"organisation":{"id":656435,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":668664,"oneLine":"51 Av Du Mal De Lattre De Tassigny","addressLine1":"51 Av Du Mal De Lattre De Tassigny","addressLine2":"","addressLine3":"","addressLine4":"","city":"Creteil","postcode":"94000","country":2012,"countryName":"France"},"phone":"+33149813785","email":"philippe.lecorvoisier@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":2571643,"firstName":"Philippe","lastName":"Le CORVOISIER","telephone":"+33149813785","email":"philippe.lecorvoisier@aphp.fr","title":"2"},"departmentName":"Centre d’Investigation Clinique"},{"id":2319943,"organisationAddressInfo":{"id":622062,"organisation":{"id":659954,"type":"Laboratory/Research/Testing facility","typeCode":"9","name":"Commissariat a l'Energie Atomique et aux Energies Alternatives","commercial":true,"isBusinessKeyValidated":true,"businessKey":"ORG-100023253","organisationLocationStatus":"Active"},"address":{"addressId":672591,"oneLine":"4 Place Du General Leclerc","addressLine1":"4 Place Du General Leclerc","addressLine2":"","addressLine3":"","addressLine4":"","city":"Orsay Cedex","postcode":"91401","country":2012,"countryName":"France"},"phone":"+33169867701","email":"Vincent.LEBON@cea.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100023253"},"personInfo":{"id":2571644,"firstName":"Vincent","lastName":"LEBON","telephone":"+33169867701","email":"Vincent.LEBON@cea.fr"},"departmentName":"Service Hospitalier Frédéric Joliot - SHFJ"},{"id":2319940,"organisationAddressInfo":{"id":618582,"organisation":{"id":656453,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Assistance Publique Hopitaux De Paris","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100004082","organisationLocationStatus":"Active"},"address":{"addressId":668683,"oneLine":"51 Av Du Mal De Lattre De Tassigny","addressLine1":"51 Av Du Mal De Lattre De Tassigny","addressLine2":"","addressLine3":"","addressLine4":"","city":"Creteil","postcode":"94000","country":2012,"countryName":"France"},"phone":"+33149812647","email":"blanche.bapst@aphp.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100004082"},"personInfo":{"id":2571641,"firstName":"Blanche","lastName":"BAPST","telephone":"+33149812647","email":"blanche.bapst@aphp.fr","title":"1"},"departmentName":"Service de Neuroradiologie"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":29883,"type":"INITIAL","status":"Authorised","ctNumber":"2024-516022-63-00","trialStatus":"Authorised","submissionDate":"2024-10-14","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-18"},"partIIInfo":[{"id":144425,"mscId":40822,"mscInfo":{"id":40822,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-11-05","decision":"authorized","decisionDate":"2024-11-06","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-11-06"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-11-06","ctMSCsByApplication":[{"id":40822,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":45377,"applicationId":29883,"mscId":40822,"mscName":"France","decisionDate":"2024-11-06T17:16:25.757","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":144425,"part1Id":45200,"applicationType":"INITIAL","isRMS":true}]},{"id":65354,"type":"NON SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-516022-63-00","trialStatus":"Authorised","submissionDate":"2025-09-17","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-18"},"partIIInfo":[{"id":242137,"mscId":40822,"mscInfo":{"id":40822,"mscName":"France","countryOrganisationId":2012,"decision":"authorized","decisionDate":"2024-11-06","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-11-06"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-09-17","ctMSCsByApplication":[{"id":40822,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"NSM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":89795,"applicationId":65354,"mscId":40822,"mscName":"France","decisionDate":"2025-09-17T16:31:55.82","decision":"authorized","eventType":"decision","part2Id":242137,"part1Id":100785,"applicationType":"NON SUBSTANTIAL MODIFICATION","isRMS":true}]},{"id":87019,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-516022-63-00","trialStatus":"Authorised","submissionDate":"2026-07-17","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-11"},"partIIInfo":[{"id":330244,"mscId":40822,"mscInfo":{"id":40822,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2026-08-12","decision":"authorized","decisionDate":"2024-11-06","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-11-06"},"applicationStatusCode":"Authorised"}],"decisionDate":"2026-08-13","ctMSCsByApplication":[{"id":40822,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":137670,"applicationId":87019,"mscId":40822,"mscName":"France","decisionDate":"2026-08-13T15:22:52.623","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":330244,"part1Id":140223,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":40822,"firstDecisionDate":"2024-11-06T17:16:25.757","lastDecisionDate":"2026-08-13T15:22:52.623","mscPublicStatusCode":4}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2021-004141-20"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":40822,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2024-03-21"},{"notificationType":"START_OF_RECRUITMENT","date":"2024-03-21"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_Addendum-Protocol_2024-516022-63-00_Annexe-EIG","uuid":"c9d2897d-7af4-496b-a2e4-e3dd74168bca","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1.0","systemVersion":"1"},{"title":"D1_Addendum-Protocol_2024-516022-63-00_Marquage-CE","uuid":"06dfd620-e865-4435-bff4-9359e82b01e2","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":6,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1","systemVersion":"1"},{"title":"D1_Addendum-Protocol_2024-516022-63-00_Notification-EIG","uuid":"729e90dc-60c0-450d-b634-5deec066285b","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1.0","systemVersion":"1"},{"title":"D1_Addendum-Protocol_2024-516022-63-00_Notification-grossesse","uuid":"2990c266-4889-4429-a7d8-b542367d0795","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1.0","systemVersion":"1"},{"title":"D4_Patient facing documents_Cahier-neurologue","uuid":"cfb11eeb-57f1-43ee-850a-9625f455b772","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_Cahier-neuropsychologue","uuid":"b258090d-14f7-4a71-ad73-de66a5ea4cc6","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"1","systemVersion":"1"},{"title":"D4_Patient facing documents_Carte-participation","uuid":"e290b6c5-284d-41d1-8ded-50d8435b5af9","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"2.0","systemVersion":"2"},{"title":"D1_Protocol 2024-516022-63-00-FP","uuid":"a17ec108-bce0-471a-b05d-3585fda38d41","documentType":"104","documentTypeLabel":"Protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"4.0","systemVersion":"2"},{"title":"D1_Protocol Synopsis_FR 2024-516022-63-00","uuid":"c6c41ee2-8009-47e7-916b-d281df7b2bc9","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":140223,"manualVersion":"4.0","systemVersion":"1"},{"title":"K1_Recruitment arrangements","uuid":"5cac59cc-0180-4ae8-b217-edeccdffd810","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"1.0","systemVersion":"2"},{"title":"L1_SIS and ICF patient","uuid":"1c65c695-5a80-42a6-9431-d25a48e74d76","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"2.2","systemVersion":"1"},{"title":"L1_SIS and ICF volontaire-sain","uuid":"8f488320-0c46-4f57-96be-15fad064bc02","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"2.2","systemVersion":"1"},{"title":"L1_SIS and ICF parental authority","uuid":"bfc9734d-2072-431b-8d1e-05f22e96d94a","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"2.2","systemVersion":"1"},{"title":"L2_Other subject information material recruitment Volontaires sains","uuid":"178567a0-b448-4591-9dbb-500cbc83b5fb","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"1.1","systemVersion":"1"},{"title":"L2_Other subject information material recruitment Patient","uuid":"c150f6d3-7176-430c-8f65-c567a7a9e409","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","languageCode":10,"fileType":"PDF","associatedEntityId":330244,"manualVersion":"1.1","systemVersion":"1"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}